[1]
. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of Radioactive Substances Advisory Committee. Nuclear medicine communications. 2000 Jan:21 Suppl():S1-93
[PubMed PMID: 10732169]
[2]
Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A. The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer treatment reviews. 2019 Jul:77():44-56. doi: 10.1016/j.ctrv.2019.06.002. Epub 2019 Jun 19
[PubMed PMID: 31260900]
[3]
McCarten KM, Nadel HR, Shulkin BL, Cho SY. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatric radiology. 2019 Oct:49(11):1545-1564. doi: 10.1007/s00247-019-04529-8. Epub 2019 Oct 16
[PubMed PMID: 31620854]
[4]
Pauls S, Buck AK, Hohl K, Halter G, Hetzel M, Blumstein NM, Mottaghy FM, Glatting G, Krüger S, Sunder-Plassmann L, Möller P, Hombach V, Brambs HJ, Reske SN. Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin. Nuclear medicine. 2007:46(1):9-14; quiz N1-2
[PubMed PMID: 17299649]
[5]
Steinert HC. PET and PET-CT of lung cancer. Methods in molecular biology (Clifton, N.J.). 2011:727():33-51. doi: 10.1007/978-1-61779-062-1_3. Epub
[PubMed PMID: 21331927]
[6]
Chao F, Zhang H. PET/CT in the staging of the non-small-cell lung cancer. Journal of biomedicine & biotechnology. 2012:2012():783739. doi: 10.1155/2012/783739. Epub 2012 Mar 7
[PubMed PMID: 22577296]
[7]
Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Ryschon K. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest. 1997 Aug:112(2):416-22
[PubMed PMID: 9266877]
[8]
Cerfolio RJ, Ojha B, Bryant AS, Bass CS, Bartalucci AA, Mountz JM. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. The Annals of thoracic surgery. 2003 Sep:76(3):861-6
[PubMed PMID: 12963217]
[9]
Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M, De Wever W, Coosemans W, Decker G, De Leyn P, Deneffe G, Van Raemdonck D, Mortelmans L. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Annals of surgery. 2000 Dec:232(6):743-52
[PubMed PMID: 11088069]
Level 1 (high-level) evidence
[10]
Chen YK, Kao CH, Liao AC, Shen YY, Su CT. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer research. 2003 Sep-Oct:23(5b):4357-61
[PubMed PMID: 14666651]
[11]
Unger JB, Ivy JJ, Connor P, Charrier A, Ramaswamy MR, Ampil FL, Monsour RP. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecologic oncology. 2004 Jul:94(1):212-6
[PubMed PMID: 15262145]
[12]
Shell J, Keutgen XM, Millo C, Nilubol N, Patel D, Sadowski S, Boufraqech M, Yang L, Merkel R, Atallah C, Herscovitch P, Kebebew E. 68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor. International journal of endocrine oncology. 2018 Feb:5(1):IJE04. doi: 10.2217/ije-2017-0005. Epub 2018 Feb 2
[PubMed PMID: 30112163]
[13]
Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016 Nov:45(10):1386-1393
[PubMed PMID: 27622342]
Level 2 (mid-level) evidence
[14]
Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Højgaard L, Kjaer A. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Jun:56(6):847-54. doi: 10.2967/jnumed.115.156539. Epub 2015 May 7
[PubMed PMID: 25952736]
[15]
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Jun:51(6):875-82. doi: 10.2967/jnumed.109.066134. Epub 2010 May 19
[PubMed PMID: 20484441]
[16]
Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. European journal of nuclear medicine and molecular imaging. 2003 Mar:30(3):403-10
[PubMed PMID: 12634969]
[17]
Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Långsjö J, Salmi J, Välimäki M, Någren K, Nuutila P. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Jun:45(6):972-9
[PubMed PMID: 15181132]
[18]
Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension (Dallas, Tex. : 1979). 2001 Jul:38(1):6-8
[PubMed PMID: 11463751]
[19]
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. European journal of nuclear medicine and molecular imaging. 2010 Mar:37(3):484-93. doi: 10.1007/s00259-009-1294-7. Epub 2009 Oct 28
[PubMed PMID: 19862519]
[20]
Wang M, Xu L, Gao M, Miller KD, Sledge GW, Zheng QH. [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C. Bioorganic & medicinal chemistry letters. 2011 Mar 15:21(6):1649-53. doi: 10.1016/j.bmcl.2011.01.100. Epub 2011 Jan 31
[PubMed PMID: 21320780]
[21]
Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations. Neurobiology of aging. 2015 Sep:36(9):2475-82. doi: 10.1016/j.neurobiolaging.2015.05.020. Epub 2015 Jun 6
[PubMed PMID: 26159621]
[22]
Shimada H, Hirano S, Sinotoh H, Ota T, Tanaka N, Sato K, Yamada M, Fukushi K, Irie T, Zhang MR, Higuchi M, Kuwabara S, Suhara T. Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study. International journal of geriatric psychiatry. 2015 Nov:30(11):1105-13. doi: 10.1002/gps.4338. Epub 2015 Aug 17
[PubMed PMID: 26280153]
[23]
Valotassiou V, Malamitsi J, Papatriantafyllou J, Dardiotis E, Tsougos I, Psimadas D, Alexiou S, Hadjigeorgiou G, Georgoulias P. SPECT and PET imaging in Alzheimer's disease. Annals of nuclear medicine. 2018 Nov:32(9):583-593. doi: 10.1007/s12149-018-1292-6. Epub 2018 Aug 20
[PubMed PMID: 30128693]
[24]
Fernández S, Giglio J, Reyes AL, Damián A, Pérez C, Pérez DI, González M, Oliver P, Rey A, Engler H, Cerecetto H. 3-(Benzyloxy)-1-(5-[(18)F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. Future medicinal chemistry. 2017 Jun:9(10):983-994. doi: 10.4155/fmc-2017-0023. Epub 2017 Jun 20
[PubMed PMID: 28632402]
[25]
Xu Z, Arbizu J, Pavese N. PET Molecular Imaging in Atypical Parkinsonism. International review of neurobiology. 2018:142():3-36. doi: 10.1016/bs.irn.2018.09.001. Epub 2018 Oct 8
[PubMed PMID: 30409257]
[26]
Pelletier-Galarneau M, Ruddy TD. PET/CT for Diagnosis and Management of Large-Vessel Vasculitis. Current cardiology reports. 2019 Mar 18:21(5):34. doi: 10.1007/s11886-019-1122-z. Epub 2019 Mar 18
[PubMed PMID: 30887249]
[27]
Takalkar A, Mavi A, Alavi A, Araujo L. PET in cardiology. Radiologic clinics of North America. 2005 Jan:43(1):107-19, xi
[PubMed PMID: 15693651]
[28]
Weinstein EA, Ordonez AA, DeMarco VP, Murawski AM, Pokkali S, MacDonald EM, Klunk M, Mease RC, Pomper MG, Jain SK. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Science translational medicine. 2014 Oct 22:6(259):259ra146. doi: 10.1126/scitranslmed.3009815. Epub
[PubMed PMID: 25338757]
[29]
van der Bruggen W, Bleeker-Rovers CP, Boerman OC, Gotthardt M, Oyen WJ. PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Seminars in nuclear medicine. 2010 Jan:40(1):3-15. doi: 10.1053/j.semnuclmed.2009.08.005. Epub
[PubMed PMID: 19958846]
Level 1 (high-level) evidence
[30]
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation--current and emerging clinical applications. Clinical radiology. 2015 Jul:70(7):787-800. doi: 10.1016/j.crad.2015.03.010. Epub 2015 Apr 25
[PubMed PMID: 25917543]
[31]
Rini JN, Bhargava KK, Tronco GG, Singer C, Caprioli R, Marwin SE, Richardson HL, Nichols KJ, Pugliese PV, Palestro CJ. PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. Radiology. 2006 Mar:238(3):978-87
[PubMed PMID: 16505395]
[32]
Bhattacharya A, Kochhar R, Aggrawal K, Sharma S, Mittal BR. 18F-FDG and FDG-labeled leukocyte PET/CT in peritoneal tuberculosis. Clinical nuclear medicine. 2014 Oct:39(10):904-5. doi: 10.1097/RLU.0000000000000335. Epub
[PubMed PMID: 24368537]
[33]
Bhattacharya A, Kochhar R, Khaliq A, Sharma S, Mittal BR. Incidental detection of colonic inflammation on PET/CT using 18F-FDG-labeled autologous leukocytes. Clinical nuclear medicine. 2013 Feb:38(2):e101-2. doi: 10.1097/RLU.0b013e31825b253f. Epub
[PubMed PMID: 23334139]
[34]
Yilmaz S, Asa S, Ozhan M, Halac M. Graft infection imaging with FDG and FDG-labeled leukocytes. Internal medicine (Tokyo, Japan). 2013:52(9):1009-10
[PubMed PMID: 23648725]
[35]
Akaike G, Itani M, Shah H, Ahuja J, Yilmaz Gunes B, Assaker R, Behnia F. PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations. Radiographics : a review publication of the Radiological Society of North America, Inc. 2018 Sep-Oct:38(5):1536-1549. doi: 10.1148/rg.2018180053. Epub 2018 Aug 17
[PubMed PMID: 30118393]
[36]
Małkowski B, Serafin Z, Glonek R, Suwała S, Łopatto R, Junik R. The Role of (18)F-FDG PET/CT in the Management of the Autoimmune Thyroid Diseases. Frontiers in endocrinology. 2019:10():208. doi: 10.3389/fendo.2019.00208. Epub 2019 Apr 5
[PubMed PMID: 31024448]
[37]
Kubota K, Yamashita H, Mimori A. Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. Seminars in nuclear medicine. 2017 Jul:47(4):408-424. doi: 10.1053/j.semnuclmed.2017.02.005. Epub 2017 Apr 11
[PubMed PMID: 28583280]
[38]
Azad GK, Siddique M, Taylor B, Green A, O'Doherty J, Gariani J, Blake GM, Mansi J, Goh V, Cook GJR. Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of (18)F-Fluoride Metabolic Flux Than with Measurement of (18)F-Fluoride PET/CT SUV? Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Mar:60(3):322-327. doi: 10.2967/jnumed.118.208710. Epub 2018 Jul 24
[PubMed PMID: 30042160]
[39]
Roef M, Vogel WV. The effects of muscle exercise and bed rest on [18F]methylcholine PET/CT. European journal of nuclear medicine and molecular imaging. 2011 Mar:38(3):526-30. doi: 10.1007/s00259-010-1638-3. Epub 2010 Oct 22
[PubMed PMID: 20967443]